Monopar Therapeutics (NASDAQ: MNPR)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-11 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.210 | -0.220 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Monopar Therapeutics (NASDAQ: MNPR) through any online brokerage.
Other companies in Monopar Therapeutics’s space includes: Humanigen (NASDAQ:HGEN), ABVC BioPharma (NASDAQ:ABVC), Indaptus Therapeutics (NASDAQ:INDP), Abeona Therapeutics (NASDAQ:ABEO) and Sio Gene Therapies (NASDAQ:SIOX).
The latest price target for Monopar Therapeutics (NASDAQ: MNPR) was reported by HC Wainwright & Co. on Monday, November 1, 2021. The analyst firm set a price target for 9.00 expecting MNPR to rise to within 12 months (a possible 381.28% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Monopar Therapeutics (NASDAQ: MNPR) is $1.87 last updated Today at August 15, 2022, 8:00 PM UTC.
There are no upcoming dividends for Monopar Therapeutics.
Monopar Therapeutics’s Q3 earnings are confirmed for Friday, November 11, 2022.
There is no upcoming split for Monopar Therapeutics.
Monopar Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.